Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint

Abdul J Sankoh1, Ralph B D'Agostino, Mohammad F Huque

  • 1Global Biostatistics, Aventis Pharmaceuticals, P. O. Box 6890, 200 Crossing Boulevard, BX2-300E, Bridgewater, NJ 08807, U.S.A. abdul.sankoh@aventis.com

Statistics in Medicine
|October 1, 2003
PubMed

Insights

Designing clinical trials often requires selecting a single primary endpoint. This paper explores practical strategies for choosing and analyzing efficacy outcomes in trials with multiple endpoints.

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Drug Development

Background:

  • Selecting a single primary endpoint is ideal for clinical trial design and analysis.
  • This ideal is often unachievable due to disease complexity or trial constraints.

Purpose of the Study:

  • To examine practical decision-making for selecting efficacy outcome measures in clinical trials.
  • To address scenarios involving inherent multiplicity components in clinical trial endpoints.

Main Methods:

  • Review of clinical decision-making scenarios.
  • Analysis of efficacy outcome measures in the context of multiplicity.

Main Results:

  • Identification of practical approaches for endpoint selection.
  • Strategies for analyzing data with multiple efficacy outcomes.

Conclusions:

  • Effective selection and analysis of multiple endpoints are crucial for clinical trials.
  • Practical strategies can guide decision-making in complex trial designs.

Related Concept Videos

Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...